Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 50 of 52 for:    Developmental Disabilities | Recruiting Studies | NIH

Vascular Disease Discovery Protocol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03538639
Recruitment Status : Recruiting
First Posted : May 28, 2018
Last Update Posted : November 11, 2019
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) )

Brief Summary:

Background:

Some genetic diseases put increase the risk of heart and blood diseases, which are the number one cause of death and disability in the U.S. Researchers want to study diseases of the heart and/or blood vessels. They want to collect data and specimens from affected people, their family members, and healthy people.

Objective:

To study diseases of the heart and/or blood vessels.

Eligibility:

People age 2 and older who may have genetic disease affecting the heart and/or blood vessels Their relatives

Healthy volunteers

Design:

Participants will be screened with a medical history, physical exams, and imaging tests. Participants may have a few visits or visits for 2 weeks or more. This will depend on their age and disease status. Visits may include:

Photographs of the face and body

Heart tests

Samples taken of blood, urine, saliva, skin, and/or tissue

Scans. For some, a dye may be injected into a vein.

A six-minute walk test

Lung tests. For some, participants will blow into a tube. For others, they will breathe in a gas from a mask, have a small injection, then have a scan.

Stress tests while walking on a treadmill or riding a stationary bike

Ultrasound of veins and arteries

Devices outside the body testing the stiffness and function of arteries

Eye exam and eye tests. For some, a dye may be injected in a vein.

Blood pressure tests

Measurements of blood flow under the skin and in the arms and fingernail blood vessels

Devices outside the body testing flexibility of the blood vessels and skin, and skin temperature


Condition or disease
Vascular Dysfunction Genetic Mutations Genetic Predisposition

Detailed Description:
The NIH provides a unique opportunity for research scientists to participate in the bench-to-bedside process, which is essential for the full implementation of translational medicine programs. The study of rare monogenetic and undiagnosed diseases is a complex bedside-to-bench-to-bedside endeavor. Recent studies show that rare genetic variants are more likely than common variants to have deleterious effects on protein structure, function, and/or expression, possibly leading to clinically relevant events. Studies of large patient populations offer the opportunity to identify rare genetic variants underlying human disease and will have impactful implications for human health. We propose to characterize the etiology and natural history of rare and orphan diseases with vascular phenotypes. We will also study rare genetic modifiers and identify novel disease mechanisms contributing to common vascular diseases. Subsequent disease-related protocols may be developed based on findings from subjects enrolled in this protocol for further intensive natural history studies and potential innovative therapeutic studies. In addition to its role in investigating individuals who are of interest to the Translational Vascular Medicine Branch (TVMB) of the NHLBI, this protocol can provide a possible avenue for admitting subjects from other NIH programs, such as the NIH Undiagnosed Diseases Program, the Center for Human Immunology Trans-institute program or other NIH protocols where subjects exhibit vascular phenotypes.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 9999 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Vascular Disease Discovery Protocol
Actual Study Start Date : July 30, 2018
Estimated Primary Completion Date : November 30, 2027
Estimated Study Completion Date : May 15, 2037

Resource links provided by the National Library of Medicine


Group/Cohort
1
Adult index cases (affected) and relatives (affected and unaffected)
2
Child index cases (affected) and child relatives (affected and unaffected)
3
Healthy adult volunteers



Primary Outcome Measures :
  1. Rapid initiation of new, disease-specific investigations to enable the collection of data and biospecimens on affected subjects, their family members and healthy controls, and to assist in the generation of diagnoses and further the understandin... [ Time Frame: Ongoing ]
    understanding of disease pathophysiology in subjects with uncommon vascular disease presentation


Secondary Outcome Measures :
  1. improve diagnosis, identify biomarkers, develop outcome measures, create centers of expertise and provide the foundation for therapy development. [ Time Frame: ongoing ]
    improve diagnosis, identify biomarkers, develop outcome measures, create centers of expertise and provide the foundation for therapy development.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 100 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
We expect to enroll an unlimited number of subjects. The study population will be divided into groups that reflect both the potential studies that may be performed in distinct groups and the risk to benefit analysis for these groups. The appendices at the end of the protocol describe possible procedures and risk profiles for all the study subjects. Vulnerable populations, including pregnant women, children and cognitively impaired persons, may participate in this study.@@@The groups include:@@@1.Adult index cases (affected) and relatives (affected and unaffected)@@@2.Child index cases (affected) and child relatives (affected and unaffected)@@@3.Healthy adult volunteers
Criteria
  • INCLUSION CRITERIA:
  • Affected or unaffected adult and child cohorts (including genetic carriers or non-carriers as reference biospecimen) are eligible.
  • Pregnant and nursing women are eligible to participate in this study if they have been referred with a known or suspected pathology, if they are a relative of an index case with a known or suspected pathology.
  • Healthy pregnant and nursing women may participate as healthy volunteers for minimal risk procedures
  • Healthy adult volunteers must be 18 years of age or older, must agree to have blood or tissue samples studied and potentially stored for future research.
  • Unaffected and unrelated children above 2 years of age are eligible to participate in this study as healthy volunteers

EXCLUSION CRITERIA:

  • Healthy volunteers unable to give informed consent or who decline to have blood drawn and/or tissue studies or who do not consent to have samples stored for future research may be excluded from this study.
  • Healthy volunteers who are pregnant or nursing will be excluded from procedures that would expose them to more than minimal risk as well as to radiation exposure.
  • Cognitively impaired individuals who are not affected or not related to affected subjects.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03538639


Contacts
Layout table for location contacts
Contact: Elisa A Ferrante, Ph.D. (301) 451-3457 elisa.ferrante@nih.gov

Locations
Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov   
Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Layout table for investigator information
Principal Investigator: Manfred Boehm, M.D. National Heart, Lung, and Blood Institute (NHLBI)

Additional Information:
Layout table for additonal information
Responsible Party: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier: NCT03538639     History of Changes
Other Study ID Numbers: 180108
18-H-0108
First Posted: May 28, 2018    Key Record Dates
Last Update Posted: November 11, 2019
Last Verified: July 18, 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) ):
Etiology of Rare and Orphan Diseases with Vascular Phenotype
Natural History of Rare and Orphan Diseases with Vascular Phenotype
Pathophysiology of Uncommon Vascular Diseases
Undiagnosed Diseases
Rare Human Diseases with Vascular Features
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Disease Susceptibility
Genetic Predisposition to Disease
Cardiovascular Diseases
Disease Attributes
Pathologic Processes